Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19-03-2020 to 28-04-2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Guideline study performed under GLP. All relevant validity criteria were met.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Version / remarks:
- Japanese Ministry of Economy, Trade and Industry, Japanese Ministry of Health, Labor and Welfare and Japanese Ministry of Agriculture, Forestry and Fisheries (24 November 2000)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: ICH S2(R1) guideline
- Version / remarks:
- June 2012 (ICH S2(R1) Federal Register
- Deviations:
- not specified
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
Test material
- Reference substance name:
- {2-[(2-methylundec-1-en-1-yl)oxy]ethyl}benzene
- Cas Number:
- 2489743-82-8
- Molecular formula:
- C20H32O
- IUPAC Name:
- {2-[(2-methylundec-1-en-1-yl)oxy]ethyl}benzene
- Test material form:
- liquid
- Details on test material:
- - Physical state: Liquid
- Storage condition of test material: Dry area, protected from light, in a refrigerator (temp 2-8°C), store in a closed container with silica gel after first opening.
- Other: colourless liquid
Constituent 1
Method
- Target gene:
- histidine or tryptophan locus
Species / strainopen allclose all
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Additional strain / cell type characteristics:
- not applicable
- Species / strain / cell type:
- E. coli WP2 uvr A pKM 101
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- Type and composition of metabolic activation system: Rat liver S9
- source of S9: Purchased from recognised supplier (dates within full study report) ; S9 Microsomal fraction: Lot No. 4189
- method of preparation of S9 mix: Documented in the full study report. Stored at -80ºC
- concentration or volume of S9 mix and S9 in the final culture medium: 10% S9
- quality controls of S9 (e.g., enzymatic activity, sterility, metabolic capability): A Certificate of S9 QC and Production Certificate including Activity is presented in the full study report. Additionally, prior to testing each batch was subjected to in-house testing to assess batch-to-batch variation using promutagens: cyclophosphamide and benzo[a]pyrene (TA1535 and TA98, respectively) and was found to be acceptable. Furthermore, concurrent positive control substances all produced marked increases in the number of revertant colonies and the activity of the S9 fraction was found to be satisfactory. - Test concentrations with justification for top dose:
- Experiment 1 (plate incorporation method):
All strains (presence of S9-mix): 0, 1.6, 5, 16, 50, 160, 500, 1600 and 5000 µg/plate
All strains (absence of S9-mix): 0, 1.6, 5, 16, 50, 160, 500, 1600 and 5000 µg/plate
On the day of dosing and on the day of scoring, precipitate was seen at and above 500 μg (1.73 μmol) per plate for all five strains in the presence and absence of S9 mix.
There was no evidence of cytotoxicity as indicated by reductions in the growth of the background lawns or in the incidence of spontaneous revertant colonies.
Experiment 2 (pre-incubation method): Eight to ten test item dose levels were selected in Experiment 2 in order to achieve both a minimum of four non-toxic doses and the toxic/guideline limit of the test item. The dose levels were selected based on the results of Experiment 1.
All strains (absence of S9-mix): 0, 1.6, 5, 16, 50, 160, 500, 1600 and 5000 µg/plate
All strains (presence of S9-mix): 0, 1.6, 5, 16, 50, 160, 500, 1600 and 5000 µg/plate
On the day of dosing and on the day of scoring, precipitate was seen at and above 500 μg (1.73 μmol) per plate for all five strains in the presence and absence of S9 mix.
Evidence of cytotoxicity as indicated by reductions in the growth of the background lawns or in the incidence of spontaneous revertant colonies was seen at 5000 μg (1.73 μmol) per plate for all five strains in the absence of S9 mix. There was no evidence of cytotoxicity for any of the five strains in the presence of S9 mix. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: dimethylsulphoxide (DMSO)
- Justification for choice of solvent/vehicle: The test item was miscible in DMSO at 100 mg/mL in solubility checks performed. DMSO was selected as the vehicle as a preferred solvent according to guideline(s).
- Other: Formulated concentrations would be adjusted/increased to allow for the stated water/impurity content, as applicable.. See 'Test Material Information' for further details, as applicable.
Controlsopen allclose all
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- 2-nitrofluorene
- sodium azide
- other: Potassium dichromate
- Remarks:
- Without metabolic activation S9
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-Aminoanthracene
- Remarks:
- With metabolic activation S9 ; Each batch was subjected to in-house testing to assess batch-to-batch variation using promutagens: cyclophosphamide and benzo[a]pyrene (TA1535 and TA98, respectively) and was found to be acceptable.
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: Experiment 1. in medium; in agar (plate incorporation) ; Experiment 2. in medium; in agar (pre-incubation).
The test item was administered in solvent (DMSO) at a volume of 100 μL per plate for the plate incorporation method and a volume of 50 μL per plate when the liquid pre-incubation method was employed, within a maximum of two hours of formulation. For each test, a stock solution of test item in the solvent, DMSO, was prepared and then diluted in the same solvent to formulate the required test solutions. The solutions of test 1: A: 50 mg/mL (or 173 mmol/L) through H: 0.016 mg/mL (or 0.0555 mmol/L) ; test 2: I: 100 mg/mL (or 347 mmol/L) through P: 0.032 mg/mL (or 0.0111 mmol/L) are documented in the full study report.
DURATION
- Exposure duration:
Experiment 1 (plate incorporation method) : Briefly, frozen aliquots of the bacterial strains (-70°C or lower) were incubated overnight (8 to 10 hours) at 37°C in an orbital incubator (120 rpm) in nutrient broth. For strains TA98, TA100 and uvrA/pKM101, the nutrient broth was supplemented with ampicillin at 25 μg/mL. Aliquots (100 μL each) of bacterial culture were mixed with 100 μL of solvent, positive control or test formulation dilution and 500 μL of sodium phosphate buffer or S9 mix. Finally, 2 mL of molten 0.6% agar maintained at approximately 50°C and supplemented with low concentrations of biotin and histidine (each at 0.05 mmol/L) for the S. typhimurium strains, and tryptophan (0.018 mmol/L) for the E. coli strain, was added. The mixture was immediately poured onto minimal glucose agar plates and incubated for 3 days at 37°C. There were three plates in all solvent control, test item and positive control groups. After incubation at 37°C for 3 days, all plates were examined both macroscopically and microscopically for evidence of cytotoxicity, precipitates and any other effect relevant to the interpretation of the test. Microscopic examination was used to check the condition of the histidine/tryptophan-requiring microcolonies that make up the background lawns. Revertant (his+, trp+) colony numbers were scored using a Sorcerer Colony Counter. Manual counts may be performed, where automated counting cannot be performed: e.g. colonies spreading, colonies on the edge of the plates and artefacts on the plates, thus distorting the actual plate count.
Experiment 2 (pre-incubation method) : Aliquots (100 μL each) of bacterial culture were mixed with 50 μL of solvent, positive control or test item formulation dilution and 500 μL of sodium phosphate buffer or S9 mix and then incubated for 60 minutes at 37°C in an orbital incubator at 120 rpm. After incubation, 2 mL of molten 0.6% agar containing biotin and histidine/tryptophan (as above) was added to the mixture and poured onto minimal glucose agar plates and incubated for a further 3 days at 37°C. There were three plates in all solvent control, test item and positive control groups. After incubation at 37°C for 3 days, all plates were examined both macroscopically and microscopically for evidence of cytotoxicity, precipitates and any other effect relevant to the interpretation of the test. Microscopic examination was used to check the condition of the histidine/tryptophan-requiring microcolonies that make up the background lawns. Revertant (his+, trp+) colony numbers were scored using a Sorcerer Colony Counter. Manual counts may be performed, where automated counting cannot be performed: e.g. colonies spreading, colonies on the edge of the plates and artefacts on the plates, thus distorting the actual plate count.
SELECTION AGENT (mutation assays): histidine or tryptophan -deficient agar
NUMBER OF REPLICATIONS: 3
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth
- Other: Viability determination: Confirmation that adequate numbers of viable bacteria were exposed to the test item was obtained from viability determinations for each strain performed concurrently with the mutagenicity test. For each tester strain, a sample of the stock overnight bacterial suspension was diluted to 10-7 in phosphate buffered saline. 200 μL of the x10^-7 dilution was spread onto each of two nutrient agar plates. The plates were then inverted and incubated at room temperature for 3 days, after which, numbers of colonies were counted and recorded. A mean viable count of at least 20 colonies per plate should be present (>109 colony forming units [cfu] per mL). - Rationale for test conditions:
- In accordance with the OECD TG 471 guidelines.
- Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1. A dose-related increase in mutant frequency over the dose range tested
2. A reproducible increase at one or more concentrations.
3. Biological relevance against in-house historical control ranges.
4. Statistical analysis of data
5. For TA1535 or TA1537, the mean number of revertant colonies of one or more doses of the test item, with or without metabolic activation was equal to or greater than 3 times the concurrent solvent control mean value (2-fold increases outside the historical control range may be assessed as equivocal); for any other strain, the mean number of revertant colonies was equal to or greater than 2 times the concurrent solvent control mean value in the presence of one or more doses of the test item, with or without metabolic activation.
A test item is considered non-mutagenic (negative) in the test system if the above criteria are not met.
In instances of data prohibiting definitive judgement about test item activity are reported as equivocal.
Results and discussion
Test resultsopen allclose all
- Key result
- Species / strain:
- E. coli WP2 uvr A pKM 101
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- See table 1 and 2
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- See table 1 and 2
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- HISTORICAL CONTROL DATA (with ranges, means and standard deviation and confidence interval (e.g. 95%)
- Positive historical control data: The current Positive HCD dataset is presented in the full study report.
- Negative (solvent/vehicle) historical control data: The current background spontaneous revertant counts in concurrent untreated controls and/or or vehicle controls ; historic negative controls are presented in the full study report.
Any other information on results incl. tables
Table 1 : Test Results: Experiment 1 with and without metabolic activation and results of concurrent positive controls
S9-Mix (+) |
Dose Level Per Plate |
Number ofrevertants(mean) +/- SD |
|||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2 uvrA/pKM101 |
|||||||
Solvent Control (DMSO) |
29 34 26 |
(30) 4.0# |
138 137 140 |
(138) 1.5 |
11 12 10 |
(11) 1.0 |
10 11 13 |
(11) 1.5 |
204 181 225 |
(203) 22.0 |
|
1.6 µg |
30 38 24 |
(31) 7.0 1.0~ |
134 125 126 |
(128) 4.9 0.9 |
12 12 8 |
(11) 2.3 1.0 |
13 10 14 |
(12) 2.1 1.1 |
199 183 178 |
(187) 11.0 0.9 |
|
5 µg |
30 25 31 |
(29) 3.2 1.0 |
127 129 135 |
(130) 4.2 0.9 |
11 12 7 |
(10) 2.6 0.9 |
12 11 11 |
(11) 0.6 1.0 |
196 195 160 |
(184) 20.5 0.9 |
|
16 µg |
29 36 29 |
(31) 4.0 1.0 |
121 142 147 |
(137) 13.8 1.0 |
12 11 16 |
(13) 2.6 1.2 |
10 12 11 |
(11) 1.0 1.0 |
153 190 193 |
(179) 22.3 0.9 |
|
50 µg |
37 31 36 |
(35) 3.2 1.2 |
126 138 128 |
(131) 6.4 0.9 |
10 10 13 |
(11) 1.7 1.0 |
10 13 15 |
(13) 2.5 1.2 |
185 178 186 |
(183) 4.4 0.9 |
|
160 µg |
27 29 26 |
(27) 1.5 0.9 |
103 107 137 |
(116) 18.6 0.8 |
12 13 12 |
(12) 0.6 1.1 |
12 12 14 |
(13) 1.2 1.2 |
193 155 180 |
(176) 19.3 0.9 |
|
500 µg |
26 P 30 P 25 P |
(27) 2.6 0.9 |
128 P 130 P 126 P |
(128) 2.0 0.9 |
11 P 10 P 9 P |
(10) 1.0 0.9 |
14 P 14 P 15 P |
(14) 0.6 1.3 |
169 P 159 P 170 P |
(166) 6.1 0.8 |
|
1600 µg |
27 P 30 P 22 P |
(26) 4.0 0.9 |
130 P 121 P 111 P |
(121) 6.1 0.9 |
11 P 13 P 13 P |
(12) 1.7 1.1 |
12 P 13 P 9 P |
(11) 2.1 1.0 |
147 P 142 P 173 P |
(154) 16.6 0.8 |
|
5000 µg |
30 P 27 P 34 P |
(30) 3.5 1.0 |
119 P 129 P 118 P |
(122) 6.1 0.9 |
10 P 11 P 17 P |
(13) 3.8 1.2 |
9 P 9 P 19 P |
(12) 5.8 1.1 |
137 P 137 P 153 P |
(142) 9.2 0.7 |
|
Positive controls S9-Mix (+) |
Name Dose Level No. ofRevertants |
2AA |
2AA |
2AA |
2AA |
2AA |
|||||
2 µg |
2 µg |
2 µg |
2 µg |
20 µg |
|||||||
1919 1743 1762 |
(1808) 96.6# 60.3~ |
2913 2376 2505 |
(2598) 280.3 18.8 |
133 157 147 |
(146) 12.1 13.3 |
109 103 102 |
(163) 22.5 14.8 |
2057 2090 1864 |
(2004) 122.1 0.9 |
||
S9-Mix (-) |
Dose Level Per Plate |
Number ofrevertants(mean) +/- SD |
|||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2 uvrA/pKM101 |
|||||||
Solvent Control (DMSO) |
30 27 29 |
(29) 1.5# |
122 122 127 |
(124) 2.9 |
14 11 13 |
(14) 1.7 |
10 11 12 |
(25) 14.0 |
168 164 166 |
(166) 2.0 |
|
1.6 µg |
26 26 32 |
(28) 3.5 1.0~ |
126 113 119 |
(119) 6.5 1.0 |
10 11 14 |
(14) 3.1 |
11 12 13 |
(18) 2.1 |
162 147 165 |
(158) 9.6 1.0 |
|
5 µg |
27 22 24 |
(24) 2.5 0.8 |
107 109 103 |
(106) 3.1 0.9 |
11 10 9 |
(15) 5.0 |
13 11 13 |
(13) 0.6 |
158 139 162 |
(153) 12.3 0.9 |
|
16 µg |
25 30 25 |
(27) 2.9 0.9 |
122 111 109 |
(114) 7.0 0.9 |
12 13 12 |
(15) 3.2 |
15 15 11 |
(19) 9.8 |
163 165 152 |
(160) 7.0 1.0 |
|
50 µg |
25 24 30 |
(26) 3.2 0.9 |
129 123 123 |
(125) 3.5 1.0 |
11 10 102 |
(16) 6.7 |
9 8 10 |
(12) 3.5 |
157 169 170 |
(165) 7.2 1.0 |
|
160 µg |
22 24 30 |
(25) 4.2 0.9 |
113 121 126 |
(120) 6.6 1.0 |
11 10 12 |
(11) 3.0 |
11 12 8 |
(21) 10.5 |
155 162 145 |
(154) 8.5 0.9 |
|
500 µg |
26 P 31 P 27 P |
(28) 2.6 1.0 |
102 P 90 P 124 P |
(105) 17.5 0.8 |
10 P 10 P 9 P |
(10) 4.5 |
11 P 12 P 7 P |
(20) 11.9 |
185 P 155 P 165 P |
(168) 15.3 1.0 |
|
1600 µg |
31 P 30 P 30 P |
(30) 0.6 1.0 |
119 P 126 P 114 P |
(120) 6.0 1.0 |
12 P 11 P 12 P |
(15) 3.0 |
11 P 10 P 10 P |
(19) 8.4 |
163 P 139 P 142 P |
(148) 13.1 0.9 |
|
5000 µg |
26 P 30 P 34 P |
(30) 4.0 1.0 |
127 P 122 P 126 P |
(125) 2.6 1.0 |
11 P 11 P 14 P |
(12) 8.1 |
11 P 13 P 11 P |
(16) 5.9 |
169 P 169 P 160 P |
(166) 5.2 1.0 |
|
Positive controls S9-Mix (-) |
Name Dose Level No. ofRevertants |
2-nitrofluorene |
Na azide |
Na azide |
9AA |
K2Cr2O7 |
|||||
1 µg |
0.5 µg |
0.5 µg |
50 µg |
25 µg |
|||||||
451 411 456 |
(439) 24.7# 15.1~ |
595 634 632 |
(620) 22.0 5.0 |
420 463 395 |
(426) 34.4 32.8 |
140 93 137 |
(123) 26.3 11.2 |
1029 954 978 |
(987) 38.3 5.9 |
N/T Not tested at this dose level
P Precipitate
# Standard deviation
~ fold increase over solvent control
Table 2 : Test Results: Experiment 2 with and without metabolic activation and results of concurrent positive controls
S9-Mix (+) |
Dose Level Per Plate |
Number ofrevertants(mean) +/- SD |
|||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2 uvrA/pKM101 |
|||||||
Solvent Control (DMSO) |
30 30 31 |
(30) 0.6# |
136 155 143 |
(145) 9.6 |
12 11 11 |
(11) 0.6 |
11 11 12 |
(11) 0.6 |
185 223 198 |
(202) 19.3 |
|
1.6 µg |
29 29 29 |
(29) 0.0 1.0~ |
134 130 152 |
(139) 11.7 1.0 |
10 8 9 |
(9) 1.0 0.8 |
12 15 10 |
(12) 2.5 1.1 |
229 210 204 |
(214) 13.1 1.1 |
|
5 µg |
35 31 37 |
(34) 3.1 1.1 |
156 141 154 |
(150) 8.1 1.0 |
10 9 8 |
(9) 1.0 0.8 |
13 13 11 |
(12) 1.2 1.1 |
198 190 199 |
(196) 4.9 1.0 |
|
16 µg |
35 30 39 |
(35) 4.5 1.2 |
147 160 162 |
(156) 8.1 1.1 |
11 11 13 |
(12) 1.2 1.1 |
14 14 14 |
(14) 0.0 1.3 |
204 191 210 |
(202) 9.7 1.0 |
|
50 µg |
36 29 32 |
(32) 3.5 1.1 |
140 146 129 |
(138) 8.6 1.0 |
12 13 12 |
(12) 0.6 1.1 |
10 12 9 |
(10) 1.5 0.9 |
225 203 184 |
(204) 20.5 1.0 |
|
160 µg |
30 24 29 |
(28) 3.2 0.9 |
119 125 149 |
(131) 15.9 0.9 |
11 10 9 |
(10) 1.0 0.9 |
12 11 13 |
(12) 1.0 1.1 |
193 190 173 |
(185) 10.8 0.9 |
|
500 µg |
31 P 32 P 39 P |
(34) 4.4 1.1 |
127 P 129 P 109 P |
(122) 11.0 0.8 |
10 P 12 P 14 P |
(12) 2.0 1.1 |
12 P 13 P 14 P |
(13) 1.0 1.2 |
186 P 192 P 193 P |
(190) 3.8 0.9 |
|
1600 µg |
32 P 42 P 39 P |
(38) 5.1 1.3 |
117 P 127 P 123 P |
(122) 5.0 0.8 |
13 P 12 P 17 P |
(14) 2.6 1.3 |
11 P 14 P 13 P |
(13) 1.5 1.2 |
219 P 191 P 170 P |
(193) 24.6 1.0 |
|
5000 µg |
33 P 36 P 32 P |
(34) 2.1 1.1 |
113 P 109 P 131 P |
(118) 11.7 0.8 |
9 P 12 P 12 P |
(11) 1.7 1.0 |
13 P 9 P 9 P |
(10) 2.3 0.9 |
180 P 211 P 185 P |
(192) 16.6 1.0 |
|
Positive controls S9-Mix (+) |
Name Dose Level No. ofRevertants |
2AA |
2AA |
2AA |
2AA |
2AA |
|||||
2 µg |
2 µg |
2 µg |
2 µg |
20 µg |
|||||||
2083 2178 2289 |
(2183) 103.1# 72.8~ |
3017 2689 2564 |
(2757) 234.0 19.0 |
155 211 193 |
(186) 28.6 16.9 |
207 201 228 |
(212) 14.2 19.3 |
1932 1917 1976 |
(1942) 30.7 9.6 |
||
S9-Mix (-) |
Dose Level Per Plate |
Number ofrevertants(mean) +/- SD |
|||||||||
TA98 |
TA100 |
TA1535 |
TA1537 |
WP2 uvrA/pKM101 |
|||||||
Solvent Control (DMSO) |
31 30 26 |
(29) 2.6# |
126 122 139 |
(129) 8.9 |
12 12 13 |
(12) 0.6 |
12 12 12 |
(12) 0.0 |
165 166 166 |
(166) 0.6 |
|
1.6 µg |
29 21 30 |
(27) 4.9 0.9~ |
126 116 97 |
(113) 14.7 0.9 |
12 13 11 |
(12) 1.0 1.0 |
11 12 11 |
(11) 0.6 0.9 |
158 159 156 |
(158) 1.5 1.0 |
|
5 µg |
32 31 29 |
(31) 1.5 1.1 |
116 97 103 |
(105) 9.7 0.8 |
11 13 14 |
(13) 1.5 1.1 |
12 10 13 |
(12) 1.5 1.0 |
166 154 162 |
(161) 6.1 1.0 |
|
16 µg |
24 23 28 |
(25) 2.6 0.9 |
116 121 116 |
(118) 2.9 0.9 |
14 13 13 |
(13) 0.6 1.1 |
11 14 10 |
(12) 2.1 1.0 |
152 144 186 |
(161) 22.3 1.0 |
|
50 µg |
25 27 29 |
(27) 2.0 0.9 |
110 100 102 |
(104) 5.3 0.8 |
12 11 11 |
(11) 0.6 0.9 |
10 11 8 |
(10) 1.5 0.8 |
130 124 136 |
(130) 6.0 0.8 |
|
160 µg |
30 24 33 |
(29) 4.6 1.0 |
112 109 102 |
(108) 5.1 0.8 |
10 12 11 |
(11) 1.0 0.9 |
11 12 11 |
(11) 0.6 0.9 |
136 143 136 |
(138) 4.0 0.8 |
|
500 µg |
34 P 28 P 29 P |
(30) 3.2 1.0 |
117 P 127 P 100 P |
(115) 13.7 0.9 |
12 P 11 P 11 P |
(11) 0.6 0.9 |
10 P 10 P 11 P |
(10) 0.6 0.8 |
139 P 136 P 137 P |
(137) 1.5 0.8 |
|
1600 µg |
31 P 30 P 26 P |
(29) 2.6 1.0 |
122 P 112 P 104 P |
(113) 9.0 0.9 |
12 P 12 P 12 P |
(12) 0.0 1.0 |
10 P 9 P 17 P |
(12) 4.4 1.0 |
135 P 130 P 137 P |
(134) 3.6 0.8 |
|
5000 µg |
0 nP 0 nP 0 nP |
(0.0) 0.0 0.0 |
0 nP 0 nP 0 nP |
(0.0) 0.0 0.0 |
0 nP 0 nP 0 nP |
(0.0) 0.0 0.0 |
0 nP 0 nP 0 nP |
(0.0) 0.0 0.0 |
107 rP 106 rP 113 rP |
(109) 3.8 0.7 |
|
Positive controls S9-Mix (-) |
Name Dose Level No. ofRevertants |
2-nitrofluorene |
Na azide |
Na azide |
9AA |
K2Cr2O7 |
|||||
1 µg |
0.5 µg |
0.5 µg |
50 µg |
25 µg |
|||||||
1511 1533 1321 |
(1455) 116.6# 50.2~ |
610 486 562 |
(553) 62.5 4.3 |
412 478 444 |
(445) 33.0 37.1 |
223 335 429 |
(332) 98.0 27.7 |
1240 1404 1437 |
(1360) 105.5 8.2 |
N/T Not tested at this dose level
R reduced survive
P Precipitate
# Standard deviation
~ fold increase over solvent control
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results:
negative
Under the conditions of this study, the test item was considered to be non-mutagenic in the presence and absence of S9 activation. - Executive summary:
The study was performed to the requirements of OECD Guideline 471 under GLP, to evaluate the potential mutagenicity of the test item in a bacterial reverse mutation assay using S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2 uvrA/pKM101 as indicator organisms in both the presence and absence of S-9 mix. The test strains were treated with the test item using the Ames (i) plate incorporation method and then (ii) pre incubation method at up to eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). A preliminary solubility assessment was conducted. As solubility was satisfactory in dimethyl sulphoxide, it was used throughout this study as the solvent for the test item. The dose range for Experiment 1 (plate incorporation method) was predetermined and was 1.6 to 5000 µg/plate (or (0.00555 to 17.3 μmol) per plate for all five indicator strains in both the presence and absence of an in vitro activation system based on S9 fraction obtained from Aroclor 1254-induced rat liver (S9 mix). The experiment was repeated in Experiment 2 (preincubation method) on a separate day using fresh cultures of the bacterial strains and fresh test item formulations. Up to eight test item dose levels were selected in Experiment 2 in order to achieve a minimum of four non-toxic dose levels and the toxic limit of the test item. The dose range employed was consistent with the Experiment 1 and ranged between 1.6 and 5000 µg/plate, in the presence or absence of S9-mix. The test item showed evidence of cytotoxicity. The minimum dose level at which cytotoxicity was seen was 5000 μg (17.3 μmol) per plate. The maximum dose level scored for revertant colonies was 5000 μg (17.3 μmol) per plate. The minimum dose at which precipitate was seen was 500 μg (1.73 μmol) per plate. The maximum dose level of the test item in both experiments were selected as the maximum recommended dose level of 5000 μg/plate or the toxic limit of the test item depending on the strain type and presence of S9-mix. The vehicle (DMSO) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated. In both experiments there were no significant increase in numbers of revertant (histidine or tryptophan-independent) colonies was seen with any of the five indicator strains either in the presence or absence of S9 mix. It was concluded that, under the conditions of this assay, the test item gave a negative, i.e. non-mutagenic response in S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2 uvrA/pKM101 in the presence and absence of S-9 mix.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.